Qed Therapeutics, A Bridgebio Company

This study is testing whether a daily oral medicine called infigratinib is safe and can help improve growth and development in infants and toddlers under 3 years old with achondroplasia, the most common form of dwarfism. Researchers will compare the medicine to a placebo (a pill …

This study aims to better understand hypochondroplasia, a rare genetic condition that causes short stature, by observing children over time. Researchers will track growth, health complications, quality of life, and physical abilities in 150 children aged 2.5 to 17. No treatment o…